Effects of Endothelin Receptor Antagonists on Renal Hemodynamics in Angiotensin II-Infused Rats on High NaCl Intake

Aso Saeed a  Gerald F. DiBona b  Gregor Guron a

a Department of Molecular and Clinical Medicine/Nephrology, Institute of Medicine, The Sahlgrenska Academy at the University of Gothenburg, Sweden, b Departments of Internal Medicine and Molecular Physiology and Biophysics, Department of Veterans Affairs Medical Center and University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

Key Words
Angiotensin II • Endothelin • Renal blood flow • Renal autoregulation • Renal medullary blood flow

Abstract
Aim: The aim was to investigate effects of selective endothelin (ET) receptor antagonists on renal hemodynamics and dynamic renal blood flow autoregulation (RBFA) in angiotensin II (Ang II)-infused rats on a high NaCl intake. Methods: Sprague-Dawley rats received Ang II (250 ng/kg/min, s.c.) and an 8 % NaCl diet for 14 days after which renal clearance experiments were performed. After baseline measurements animals were administered either: (a) saline vehicle; (b) ETA receptor antagonist BQ-123 (30 nmol/kg/min); (c) ETB receptor antagonist BQ-788 (30 nmol/kg/min); or (d) BQ-123 + BQ-788, for six consecutive 20-minute clearance periods. Results: BQ-123 reduced arterial pressure (AP) and selectively increased outer medullary perfusion versus vehicle (p<0.05). These effects were attenuated or abolished by combined BQ-123 and BQ-788. BQ-788 reduced renal blood flow and increased renovascular resistance (p<0.05). Ang II-infused rats on high NaCl intake showed abnormalities in dynamic RBFA characterized by an impaired myogenic response that were not significantly affected by ET receptor antagonists. Conclusion: In hypertensive Ang II-infused rats on a high-NaCl intake selective ET A antagonism with BQ-123 reduced AP and specifically increased OM perfusion and these effects were dependent on intact ET B receptor stimulation. Furthermore, ET receptor antagonists did not attenuate abnormalities in dynamic RBFA.
Introduction

Endothelin (ET)-1 is a potent vasoactive peptide that has important roles in the regulation of kidney function and arterial pressure (AP) [1]. Endothelin-1 exerts its biological actions through two major receptor subtypes in mammals; ET\textsubscript{A} and ET\textsubscript{B}. The vascular effects of ET-1 are influenced by the distribution and relative abundance of ET\textsubscript{A} and ET\textsubscript{B} receptors. Activation of ET\textsubscript{A} and ET\textsubscript{B} receptors on vascular smooth muscle cells (VSMCs) mediates vasoconstriction whereas activation of endothelial ET\textsubscript{B} receptors produce vasodilation which is mainly caused by activation of nitric oxide synthase (NOS) and NO [1-3]. In the kidney, ET-1 also regulates tubular sodium and water reabsorption mainly in the thick ascending limb and collecting duct (CD) [4] although there may also be effects in proximal tubules [5]. Interestingly, the highest tissue levels of ET-1 in the body are found in the renal medulla [6] where ET-1 is mainly synthesized by CD cells and acts in an autocrine and paracrine manner [1]. Endothelin-1 production by the CD is increased in natriuretic situations and ET-1 inhibits CD sodium and water reabsorption predominantly through ET\textsubscript{B} receptors on CD cells [1, 4]. However, ET-1 also modulates medullary blood flow [7, 8] and may inhibit tubular sodium reabsorption by causing medullary vasodilatation [9]. Infusion of Big ET-1 produces selective vasodilatation in the renal medulla in rats on a high NaCl intake via ET\textsubscript{B} receptors [9]. In addition, ET\textsubscript{A} receptor antagonism has been shown to reduce medullary blood flow and to blunt the pressure natriuresis relationship in rats on a high NaCl intake [9]. Furthermore, rats deficient in ET\textsubscript{B} receptors [10] and mice with collecting duct-specific deletion of ET-1 [11], ET\textsubscript{B} receptors [12], or ET\textsubscript{A} and ET\textsubscript{B} receptors [13], develop hypertension that is exaggerated by a high NaCl intake. Taken together, ET-1 in the renal medulla is involved in long-term AP regulation, particularly during high NaCl intake and exerts antihypertensive effects primarily via ET\textsubscript{B} receptors by promoting urinary sodium and water excretion. Besides the role of renal ET\textsubscript{B} receptor in regulation of AP by modulating tubular sodium and water reabsorption, ET-1 may also act as an amplifier of the pressor effects of Ang II [14]. Several factors can stimulate intrarenal ET-1 synthesis, including Ang II [15, 16]. Thus, ET-1 may contribute to hypertension in Ang II-dependent forms of hypertension. Most pressor effects of ET-1 are mediated by activation of the ET\textsubscript{A} receptor [1, 17]. The antihypertensive effect of ET\textsubscript{A} receptor antagonists has been shown to be more prominent in Ang II-infused rats on a high NaCl diet compared to those on a normal NaCl diet [18]. In line with these results ET\textsubscript{A} receptor antagonists lower AP in other salt-sensitive models of hypertension [19, 20].

We have previously shown that rats with hypertension caused by chronic Ang II-infusion and a high NaCl intake develop a marked increase in renovascular resistance and impairments in dynamic RBF autoregulation (RBFA) characterized by an abnormal myogenic response [21]. We hypothesized that ET-1 might contribute to these abnormalities in renal hemodynamics in this model. Hence, the aim of the present study was to investigate the effects of selective ET\textsubscript{A} and/or ET\textsubscript{B} receptor antagonists on intrarenal hemodynamics and dynamic RBFA in Ang II-infused rats on a high NaCl diet.

Materials and Methods

General procedures

Male Sprague-Dawley rats (Harlan, Horst, The Netherlands) weighing approximately 300 g were used. Rats had free access to chow and tap water and were kept in rooms with a controlled temperature of 24-26°C and a 12:12 h dark-light cycle. Chemicals were from Sigma (St. Louis, MO, USA) if not stated otherwise. Endothelin receptor antagonists BQ-123 and BQ-788 were purchased from Peptides Int. (Louisville, KY, USA). These agents have been widely used previously and at acceptable side effects [22-26].

Protocol

Rats received Ang II (250 ng/kg/min, s.c.) via osmotic minipumps (Alzet model 2002) and a high NaCl (HNa, 8 % NaCl) diet (Lantmännen, Sweden) for 14 days after which renal clearance experiments were
performed. After two 20-minute baseline clearance periods, rats were intravenously (i.v.) administered either: (a) isotonic saline vehicle (AngII HNa-vehicle, n=8); (b) the ET\textsubscript{A} receptor antagonist BQ-123 (30 nmol/kg/min, AngII HNa-BQ123, n=9); (c) the ET\textsubscript{B} receptor antagonist BQ-788 (30 nmol/kg/min, AngII HNa-BQ788, n=10); or (d) BQ-123 + BQ-788 (both in doses of 30 nmol/kg/min, AngII HNa-BQ123+BQ788, n=9). Based on previous studies these doses were expected to result in steady state plasma concentrations that completely block responses to both endogenous and exogenous (0.3 nmol/kg, i.v. bolus) ET-1 via ET\textsubscript{A} and ET\textsubscript{B} receptors within approximately 60 minutes [22-24]. Drugs and vehicle saline were infused in equivalent volumes of 4 ml/kg/h throughout six consecutive 20-minute clearance periods.

**Surgical preparation and measurements**

Rats were anaesthetized with thiobutabarbital (Inactin, 120 mg/kg i.p.), placed on a heating table, and surgically prepared for renal clearance experiments as described [27]. An AP catheter inserted via the femoral artery was connected to a pressure transducer (Smiths Medical, Kirchseeon, Germany) for monitoring of AP, pulsatile and mean (MAP) and heart rate (HR) using a data acquisition program (Biopac MP 150, Biopac Systems, Santa Barbara, CA, USA). Infusions of saline and drugs were administered through a femoral vein catheter. The left kidney was exposed by a flank incision and immobilized in a plastic cup. The left ureter was catheterized for urine collection. Rectal and kidney temperatures were kept at 37°C. A perivascular ultrasonic transit-time flow probe (0.7 VB, T206, Transonic Systems Inc., Ithaca, NY, USA) was placed around the left renal artery for measurement of RBF. Renal cortical (CLDF) and outer medullary (OMLDF) laser-Doppler fluxes were measured by laser-Doppler flowmetry (PF5000; Perimed, Stockholm, Sweden). Outer medullary perfusion was measured by a needle probe (411; Perimed) at a depth of 3.5 mm into the kidney, as described previously [27]. The laser-Doppler signal has been demonstrated previously to provide an adequate estimate of regional tissue blood flow in the kidney [28].

Glomerular filtration rate (GFR) was determined by measuring renal 51Cr-EDTA clearance (\textsuperscript{51}Cr-ethylenediamine tetracetic acid, Amersham Laboratories, Buckinghamshire, UK), as described [29]. Blood was sampled at the start and completion of each 20-minute clearance period and mean values of plasma radioactivity were used to calculate GFR. Arterial blood samples (0.3 ml) were replaced by equivalent volumes of 4 % bovine serum albumin in isotonic saline. Rats were infused with a total volume of 10 ml/kg/h of isotonic saline throughout. Rats were killed by an overdose of pentobarbital sodium. Renal vascular resistance (RVR) was calculated as MAP (mmHg)/RBF (ml/min/g kidney weight [KW]). Filtration fraction (FF) was calculated as GFR/RBF as haematocrit was not measured and hence renal plasma flow could not be calculated.

**Transfer function analysis**

To evaluate effects of ET receptor antagonists on dynamic RBFA, data from baseline clearance periods and the last two periods (i.e. C7+C8, 80-120 minutes after start of drug administration) were subjected to power spectral and transfer function analyses using methods previously described in detail [21]. Data over the range of frequencies for the myogenic response (0.08-0.18) and the tubuloglomerular feedback (TGF) mechanism (0.03-0.06) were analysed [21, 30, 31]. The slope of gain decrease in the frequency range of the myogenic response was determined by least squares fitting of the linear regression of gain decrease and the phase peak was estimated as the average phase value within the same frequency interval. In addition, to assess the contribution of the myogenic response to RBFA, mean gain values in the frequency range of 0.06-0.09 Hz were used to minimize corruption by TGF (<0.06 Hz) and by myogenic transients (>0.09 Hz) [21, 32].

**Statistical analysis**

All values are means±SEM. Analyses were performed using one-way analysis of variance (ANOVA). Normality was tested with the Shapiro-Wilk test and equality of variances was assessed by Levene’s test. If data were not normally distributed or had unequal variances, Kruskal-Wallis one-way ANOVA on ranks was used. Unpaired t-test or Mann–Whitney U test was used when appropriate. Bonferroni corrections were made for multiple comparisons. To reduce the number of comparisons no statistical analyses were made between groups AngII HNa-BQ123 and AngII HNa-BQ788. To assess drug effects, the area under/over the curve (AUC, AOC) for the intervention period was calculated by the trapezoidal formula using the statistical program Prism version 5 (GraphPad Software Inc., San Diego, CA). A P value <0.05 was considered statistically significant. The statistical software SPSS 17.0 (SPSS Inc., Chicago, Illinois, USA) was used.
Results

Renal hemodynamics and function at baseline

At baseline, prior to drug administration, there were no significant differences between groups in MAP, RBF, RVR or GFR (Table 1). There were statistically significant differences between groups in FF, urine flow rate and urinary sodium excretion (p<0.05, Table 1).

Renal hemodynamics and function - effects of ETA and ETB receptor antagonists

Effects of BQ-123.

BQ-123 reduced MAP versus (vs.) vehicle (p<0.05, Figure 1A). In addition, group AngII HNa-BQ123 showed a progressive increase in OMLDF vs. AngII HNa-vehicle (p<0.05) whereas total RBF and CLDF were not significantly affected (Figure 2). During the last clearance period OMLDF had increased by 29±8% vs. baseline in AngII HNa-BQ123. Combined treatment with BQ-123 and BQ-788 abolished the increase in OMLDF produced by BQ-123 alone (p<0.05, AngII HNa-BQ123+BQ788 vs. AngII HNa-BQ123, Figure 2C). BQ-123 had no statistically significant effects on GFR, urine flow rate or absolute or fractional urinary sodium excretion (Figures 3 and 4).

Effects of BQ-788.

BQ-788 caused a continuous decrease in RBF (p<0.05 vs. vehicle) and during the final clearance period RBF had decreased by 29±3% vs. baseline (Figure 2A). BQ-788 had no statistically significant effects on MAP or GFR and hence RVR and FF increased significantly vs. vehicle (p<0.05, Figures 1 and 3). BQ-788 had no statistically significant effects on cortical or outer medullary perfusion (Figure 2). Combined treatment with BQ-123 and BQ-788 abolished the effects of BQ-788 alone, and there were no statistically significant differences between groups AngII HNa-BQ123+BQ788 and AngII HNa-vehicle in RBF, RVR of FF (Figures 1B, 2A and 3B). In addition, MAP and RVR were significantly reduced (Figures 1), and HR increased (data not shown), in AngII HNa-BQ123+BQ788 vs. AngII HNa-BQ788 (p<0.05). BQ-788 had no statistically significant effects on urine flow rate or absolute or fractional urinary sodium excretion (Figure 4).

Transfer function analysis of renal blood flow autoregulation

At baseline, prior to drug administration, the normal distinct transition in gain from positive to negative values in the frequency range of the myogenic response did not occur, or was attenuated, in all groups and the corresponding local maximum in phase was missing, or blunted, indicating an impaired myogenic response (Table 2 and Figures S1-4). Supplemental figures can be seen at the authors department web-page by using the following link-address: http://www.medicine.gu.se/mkm/njurmedicin/artikelbilder/. In addition, gain values

| Table 1. Renal hemodynamics and function at baseline, prior to drug administration |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                | AngII HNa-vehicle (n=8)         | AngII HNa-BQ123 (n=9)          | AngII HNa-BQ788 (n=10)         | AngII HNa-BQ123+BQ788 (n=9)     |
| Body weight (g)                | 281±16                          | 261±11                          | 263±6                          | 262±8                           |
| MAP (mmHg)                     | 156±4                           | 146±4                           | 144±5                           | 146±2                           |
| HR (bpm)                       | 392±10                          | 373±12                          | 374±9                           | 393±6                           |
| GFR (ml/min/g KW)              | 1.40±0.04                       | 1.22±0.10                       | 1.10±0.08                       | 1.19±0.05                       |
| RBF (ml/min/g KW)              | 6.0±0.3                         | 6.1±0.3                         | 5.8±0.3                         | 6.5±0.3                         |
| RVR (mmHg/[ml/min/g KW])       | 26.4±1.6                        | 24.4±1.4                        | 25.6±1.5                        | 22.9±1.1                        |
| FF (GFR/RBF, %)                | 23.5±0.7                        | 20.4±1.7                        | 19.3±1.1*                       | 18.6±0.9*                       |
| UV (µl/min/g KW)               | 32.8±5.8                        | 45.5±11.4                       | 39.1±12.8                       | 13.5±2.3*††                    |
| UoNaV (µmol/min/g KW)          | 6.27±0.95                       | 4.67±0.83                       | 6.31±1.82                       | 2.17±0.44††                   |
| FEna (%)                       | 3.07±0.47                       | 3.89±0.92                       | 4.84±1.31                       | 1.77±0.34††                    |

Data are means±SEM of two baseline 20-minute clearance periods prior to drug administration in thiobutabarbital anesthetized rats (see Methods). MAP, mean arterial pressure; BW, body weight; HR, heart rate; GFR, glomerular filtration rate; KW, kidney weight; RBF, renal blood flow; RVR, renal vascular resistance; FF, filtration fraction; UV, urine flow rate; FEna, fractional urinary sodium excretion, UoNaV, urinary sodium excretion. * P<0.05 vs. AngII HNa-Vehicle, † P<0.05 vs. AngII HNa-BQ123 and ‡ P<0.05 vs. AngII HNa-BQ788. There were no statistically significant differences between groups in kidney weight.
Saeed/DiBona/Guron: Endothelin and Renal Hemodynamics

Fig. 1. Changes in (A) mean arterial pressure (MAP) and (B) renal vascular resistance (RVR) in response to intravenous BQ123, BQ788, BQ123 + BQ788 or vehicle isotonic saline in hypertensive Sprague-Dawley rats subjected to chronic Ang II-infusion and high NaCl (HNa) diet (see Methods). Drug administration was started at time zero (see Methods). Values are means±SEM. The area under/over the curve was used for comparisons between groups. A P value <0.05 was considered statistically significant. * P<0.05 vs. AngII HNa-Vehicle, † P<0.05 AngII HNa-BQ788 vs. AngII HNa-BQ123+BQ788.

Fig. 2. Changes in (A) renal blood flow (RBF) and renal (B) cortical (CLDF) and (C) outer medullary (OMLDF) laser-Doppler fluxes in response to intravenous BQ123, BQ788, BQ123 + BQ788 or vehicle isotonic saline in hypertensive Sprague-Dawley rats subjected to chronic Ang II-infusion and high NaCl (HNa) diet (see Methods). Drug administration was started at time zero (see Methods). Values are means±SEM. The area under/over the curve was used for comparisons between groups. A P value <0.05 was considered statistically significant. * P<0.05 vs. AngII HNa-Vehicle, † P<0.05 AngII HNa-BQ788 vs. AngII HNa-BQ123+BQ788.

Discussion

In this model of hypertension caused by chronic Ang II-infusion and a high dietary NaCl intake, renal hemodynamics is characterized by a marked increase in RVR accompanied by reduced RBF and an impaired dynamic RBFA [21]. The main findings of the present published data [21]. In general, group AngII HNa-BQ123+BQ788 showed less pronounced abnormalities compared to other groups at baseline (Table 2 and Figure S4). Endothelin receptor antagonists did not produce any statistically significant changes vs. vehicle in the investigated transfer function variables (Table 2 and Figures S1-4).

remained largely positive in the frequency range of the TGF in groups AngII HNa-vehicle, AngII HNa-BQ123 and AngII HNa-BQ788 (Table 2 and Figures S1-3). These results are in accord with our previously
study were that the selective ET\textsubscript{A} receptor antagonist BQ-123 reduced MAP and produced a selective increase in outer medullary (OM) perfusion without affecting total or cortical RBF. On the contrary, the ET\textsubscript{B} receptor antagonist BQ-788 reduced RBF and increased RVR. Finally, neither ET\textsubscript{A} and/or ET\textsubscript{B} receptor antagonists attenuated abnormalities in dynamic RBFA that were characterized by an impaired myogenic response.

BQ-123 reduced MAP in Ang II-infused rats on high NaCl intake indicating a role for ET\textsubscript{A} receptors in this model of hypertension. This result supports previous findings with ET\textsubscript{A} receptor antagonists in similar models [18, 33]. Interestingly, combined ETA and ETB receptor antagonism attenuated the reduction in MAP caused by ETA receptor antagonist alone. Furthermore, although the overall effect of BQ-788 on MAP did not reach statistical significance, we observed that BQ-788 induced a transient small increase in MAP. In accord with our finding, Boesen et al. [33] have demonstrated that ET\textsubscript{B} receptor blockade transiently enhanced the severity of hypertension in AngII-infused rats on a high NaCl intake. Taken together, these findings suggest an antihypertensive role for ET\textsubscript{B} receptors in AngII-infused animals on a high NaCl intake. Notably, selective ET\textsubscript{A} receptor antagonism with BQ-123 specifically increased OM perfusion by approximately 30 % despite reducing MAP. The vasodilation caused by BQ-123 in the renal medulla may have antihypertensive effects by increasing urinary sodium and water excretion and by facilitating pressure natriuresis [34].
In addition, an increase in OM perfusion could be beneficial by improving medullary tissue oxygenation in a situation where pronounced renal vasoconstriction could promote hypoxic tissue injury. In line with the effect on MAP, combined ET<sub>A</sub> and ET<sub>B</sub> receptor antagonism abolished the increase in OM perfusion produced by BQ-123 alone, indicating that the effect of BQ-123 was dependent on intact ET<sub>B</sub> receptor signalling. Previous results demonstrate that there is a complex interaction between ET<sub>A</sub> and ET<sub>B</sub> receptors in the regulation of renal medullary blood flow. Systemic infusion of ET-1 has been shown to selectively increase medullary perfusion via ET<sub>B</sub> receptors [7, 8, 35]. In addition, Vassileva et al. [9] showed that medullary vasodilation produced by Big ET-1, through ET<sub>B</sub> receptors, was more prominent in rats on a high NaCl intake compared to animals on normal NaCl intake. However, ET-1 has also been shown to cause renal medullary vasoconstriction via ETA receptors when infused directly into the medulla [36]. In addition, Silldorff et al. [37] demonstrated that ET-1 constricted isolated descending vasa recta in vitro and that this effect could be blocked by ET<sub>A</sub> antagonists. Taken together, a number of studies have demonstrated that ET-1 can cause both vasoconstriction and vasodilatation in the renal medulla depending on the experimental condition and the prevailing balance between ET<sub>A</sub> and ET<sub>B</sub> receptor stimulation. Considering that OM vasodilation by BQ-123 seemed to be dependent on ET<sub>B</sub> receptor stimulation in the present study one might have anticipated that selective ET<sub>B</sub> antagonism with BQ-788 should reduce OM perfusion. However, although BQ-788 tended to reduce OM perfusion this decrease did not reach statistical significance. These seemingly discrepant results are difficult to explain and need to be investigated further. Still, our results indicate that the increase in OM perfusion caused by BQ-123 was not just a consequence of removal of ET<sub>A</sub> mediated vasoconstriction but also involved vasodilation via ET<sub>B</sub> receptors.

It is feasible to hypothesize that the increase in OM perfusion caused by BQ-123, which was dependent on ET<sub>B</sub> receptor stimulation, could exert antihypertensive effects in this model by increasing urinary sodium and water excretion and facilitating pressure natriuresis [34]. In support of this antihypertensive role of ET<sub>B</sub> receptors, rats deficient in ET<sub>A</sub> receptors [10] and mice with collecting duct-specific deletion of ET-1 [11], ET<sub>B</sub> receptors [12], or ET<sub>A</sub> and ET<sub>B</sub> receptors [13], develop salt-sensitive hypertension. In addition, rats chronically treated with ET<sub>B</sub> receptor antagonist [9], and mice with collecting duct-specific deletion of ET-1 [38] show a blunted pressure natriuresis relationship. Nevertheless, the increase in OM perfusion caused by BQ-123 in the present study was not associated with increased urinary sodium and water excretion suggesting that the reduction in MAP caused by BQ-123 during the 120 minute intervention period was independent of excretory function. Hence, we speculate that BQ-123 reduced MAP in the present study mainly by causing arterial vasodilation and by
reducing total peripheral resistance. The reason why increased outer medullary perfusion was not accompanied by increased urinary sodium excretion in response to BQ-123 remains elusive. Theoretically one could speculate that the increase in medullary perfusion might not have been transmitted into an increase in renal interstitial hydrostatic pressure which is an important mediator of decreased tubular sodium reabsorption during pressure-natriuresis. Alternatively, it is possible that the experimental condition with high circulating Ang II levels could cause an increase in sodium reabsorption in distal tubular segments that would compensate for decreased passive tubular sodium reabsorption in upstream tubular segments mediated by an increase in outer medullary perfusion.

In the present study selective ET\textsubscript{B} receptor antagonism with BQ-788 caused a significant increase in RVR and a marked decrease in RBF of approximately 30%. In addition both CLDF and OMLDF clearly tended to decrease although not reaching statistical significance. Combined ET\textsubscript{B} and ET\textsubscript{A} receptor antagonism fully prevented the changes in RVR and RBF produced by BQ-788 indicating that the renal vasoconstriction was completely dependent on ETA receptor stimulation. These results are in agreement with those previously reported in normotensive animals [22, 35, 39]. Still, it may seem contradictory that selective ET\textsubscript{A} antagonism with BQ-123 alone did not have significant effects on RBF or RVR in the present study. A possible explanation is that ET\textsubscript{B} antagonism increased plasma levels of ET-1 as ET\textsubscript{B} receptors play an important role in clearance of ET-1 from the circulation [40]. Thus, increased plasma levels of ET-1 produced by ET\textsubscript{B} antagonism could have caused an exaggerated renal vasoconstrictor response through ET\textsubscript{A} receptors. However, the potential increase in plasma levels of ET-1 by ET\textsubscript{B} receptor antagonism in the present study remains hypothetical as measurements of plasma ET-1 were not performed. Interestingly, selective ET\textsubscript{B} receptor antagonism with BQ-788 in the present study had no significant effect on GFR despite reducing RBF and hence FF increased. These results suggest that ET\textsubscript{B} receptor antagonism predominantly increased RVR by constriction of efferent arterioles. Also this effect was abolished by combined ET\textsubscript{A} and ET\textsubscript{B} receptor antagonism indicating that the increase in efferent arteriolar resistance was mainly caused by ET\textsubscript{A} receptor stimulation. In accord with our findings, Inscho et al. [41] have demonstrated that ET\textsubscript{A} receptor blockade prevents ET-1-mediated vasoconstriction of efferent arterioles.

We have previously demonstrated that dynamic RBFA is impaired in Ang II-infused rats, and exaggerated by a high NaCl intake, and that these abnormalities were attenuated by the superoxide dismutase mimetic tempol [21]. As ET-1 has been shown to stimulate NADPH oxidase activity and superoxide production [42, 43] we speculated that ET receptor antagonists might attenuate abnormalities in RBFA in this model. Confirming our previous results, Ang II-infused rats on a high NaCl diet displayed marked impairment in dynamic RBFA, mainly affecting the myogenic response. However, acute administration of ET receptor antagonists did not have any significant effects on dynamic RBFA, clearly suggesting that ET-1 is not involved in these defects in autoregulatory behaviour.

Conclusion

In Ang II-infused rats on a high NaCl diet ET\textsubscript{A} antagonism with BQ-123 reduced AP and increased OM perfusion without affecting total or cortical RBF. These potentially beneficial effects were attenuated or abolished by combined ET\textsubscript{A} and ET\textsubscript{B} antagonism, clearly indicating an important role for ET\textsubscript{B} receptors in mediating the hemodynamic effects. In addition, ET receptor antagonists did not attenuate abnormalities in dynamic RBFA in this model.

Conflict of Interests

None
Acknowledgements

The technical assistance of Elisabeth Grimberg is acknowledged. This study was supported by grants from the Swedish Heart-Lung Foundation, the Göteborg Medical Society, the Swedish Medical Society, the Swedish Association for Kidney Patients, Swedish Society of Nephrology, and Britt Wennerström’s Research Foundation. G. F. DiBona was supported by research grants from the Adlerbertska Forskningsstiftelsen, The Royal Society of Arts and Sciences, Göteborg, Sweden, and Karolinska Institute, Stockholm, Sweden.

References